A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/10 (2006.01) A61K 39/116 (2006.01) C07K 14/235 (2006.01) C12N 1/21 (2006.01) A61K 38/00 (2006.01) A61K 39/00 (2006.01)
Patent
CA 2045071
ABSTRACT OF THE DISCLOSURE Novel acellular anti-pertussis vaccines are described, which comprises a non-toxic double mutant of pertussis toxin (PT), filamentous haemagglutinin (FHA) and the 69 kilodaltons protein (69Kd) taken alone or in combination with the diphtheria and tetanus anatoxin. The completely non-toxic double mutant of the PT is characterized by the fact that is comprises in the amino acid sequence of the S1 subunit the substitution of Glu 129 and of one of any other amino acid of the subunit, whose substitution brings about a decrease in toxicity, by natural amino acids. Moreover there are described purification methods for, and the characterisation of the FHA and the 69 Kd protein expressed by transformed B. pertussis W28-9K/129G strains, which produce the PT double mutant and by transformed B. pertussis W28- Tox which do not produce the PT. These proteins are particularly suitable for preparing safer and more immunogenic acellular anti-pertussis vaccine.
Bugnoli Massimo
Manetti Roberto
Marsili Ilio
Nencioni Luciano
Rappuoli Rino
Borden Ladner Gervais Llp
Chiron S.p.a.
LandOfFree
Acellular anti-pertussis vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acellular anti-pertussis vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acellular anti-pertussis vaccines will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1944425